20:01 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Novavax's RSV vaccine misses in Phase III in infants

Novavax Inc. (NASDAQ:NVAX) said its ResVax RSV vaccine missed the primary endpoint in the Phase III Prepare trial to prevent respiratory syncytial virus infection in infants via maternal immunization. In the trial's per protocol population...
23:01 , Feb 28, 2019 |  BC Extra  |  Clinical News

Novavax down after Phase III miss for RSV vaccine in infants

Novavax Inc. (NASDAQ:NVAX) lost $1.42 (67%) to $0.71 on Thursday after reporting that its ResVax RSV vaccine missed the primary endpoint in the Phase III Prepare trial to prevent respiratory syncytial virus infection in infants...
18:52 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Rat studies suggest vaccination during pregnancy with a vaccine based on RSV F and G proteins could help prevent RSV infection in offspring. The vaccine consists of Newcastle disease virus-like...
18:24 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Novavax reports positive DSMB analysis of Phase III for RSV vaccine

Novavax Inc. (NASDAQ:NVAX) presented results from an "informational analysis" of the Phase III Prepare trial of its RSV F vaccine to prevent respiratory syncytial virus (RSV) in infants via maternal immunization. Data were presented at...
22:10 , Jan 10, 2018 |  BC Extra  |  Clinical News

Novavax gains on DSMB analysis for RSV vaccine

Novavax Inc. (NASDAQ:NVAX) jumped $0.79 (59%) to $2.12 on Wednesday after presenting results from an "informational analysis" of the Phase III Prepare trial of its RSV F vaccine to prevent respiratory syncytial virus (RSV) in...
02:03 , Jan 24, 2017 |  BC Week In Review  |  Clinical News

RSV F vaccine: Ph II started

Novavax began a double-blind, placebo-controlled, Australian Phase II trial to evaluate RSV F vaccine given once or twice 21 days apart with or without aluminum phosphate or the company’s Matrix M saponin-based adjuvant in about...
23:09 , Jan 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Rat studies suggest a live attenuated RSV vaccine engineered to stably express the prefusion conformation of RSV F protein could help prevent RSV infection. The vaccine expressed an RSV F...
21:23 , Nov 18, 2016 |  BC Week In Review  |  Company News

Novavax restructuring

Novavax will reduce headcount by 164 (30%) to about 372 and will focus on its ongoing Phase III Prepare trial to vaccinate infants against respiratory syncytial virus (RSV) via maternal immunization. Last quarter, the Phase...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

RSV F vaccine: Phase III data

Top-line data from the observer-blind, U.S. Phase III Resolve trial in 11,856 adults ages >=60 showed that a single dose of 135 ug intramuscular RSV F vaccine missed the primary endpoint of reducing the proportion...